Authors
Latest:
Dr Corre on the Clinical Implications of D-VTd Treatment in Newly Diagnosed MyelomaJill Corre, PharmD, PhD, discusses the implications of using daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.
Latest:
Dr. Abdallah on Interim Efficacy Data on HPN217 in R/R Multiple MyelomaAl-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.
Latest:
Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and LustbergOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Latest:
Dr. Rettig on the Evolving Use of Triplet Regimens in mHSPCMatthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.
Latest:
Discrete Data Are Key to Realizing Electronic Health Records’ Full PotentialElectronic health record systems’ design, usability, and interoperability issues can hinder integration and use.
Latest:
Dr Hunter on the Management Ruxolitinib-Associated AEs in MyelofibrosisAnthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.
Latest:
Dr Lee on 3-Year Follow-Up Data From the ROCKstar Trial of Belumosudil in cGVHDStephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.
Latest:
Dr Mujumdar on Key Trials Evaluating Treatments for Ovarian CancerVaidehi Mujumdar, MD, discusses several key trials that have helped shift the ovarian cancer treatment paradigm.
Latest:
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCLMichael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Latest:
Dr. Bhatt on the Longitudinal Effects of Chronic Diseases in Childhood Cancer SurvivorsNeel S. Bhatt, MBBS, MPH, discusses the longitudinal effects of chronic diseases in childhood cancer survivors.
Latest:
Brigatinib in NF2-Related Schwannomatosis with Progressive TumorsScott Plotkin, MD, reviews data from a phase II study on brigatinib, a multi tyrosine kinase inhibitor, across various tumor types in patients with NF2-related schwannomatosis.
Latest:
Dr. Wesolowski on the Potential Future Utility of Trastuzumab Deruxtecan in HER2+ Breast CancerRobert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Latest:
UF Health Cancer Center Achieves National Cancer Institute DesignationThe University of Florida Health Cancer Center has received prestigious designation from the National Cancer Institute, or NCI, and joins the ranks of the country’s most distinguished cancer centers, becoming the 72nd in the United States and the only one in North Central Florida.
Latest:
Dr. Pieczonka on the Rationale to Evaluate VERU-111 in mCRPCChristopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.
Latest:
Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse EventsExpert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
Latest:
The Evolving Treatment Landscape of Small Cell Lung CancerClosing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Latest:
Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCCSoki Kashima, MD, PhD, discusses a study investigating T-cell phenotypes associated with response or resistance to checkpoint inhibitors in RCC.
Latest:
Dr. Contreras on the Use of Surgical Resection in Desmoplastic MelanomaCarlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.
Latest:
Dr Arner on the Role of SETD2 Loss in Tumor Growth and Metastasis in ccRCCEmily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.
Latest:
Novel Treatment Approaches Under Investigation for HER2+ mBCJoseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.
Latest:
Dr. Strati on the Investigation of Immunotherapy Combinations in LymphomaPaolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.
Latest:
Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-MakingAnna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.
Latest:
Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid TumorsAlberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.
Latest:
Dr Danish on Post-CAR T-Cell Bridging Radiation Therapy Eligibility in High-Risk NHLAdnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.
Latest:
Dr. Yohe on the Potential to Target RAS Mutations in Pediatric CancersMarielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.
Latest:
Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for TestingKey opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.
Latest:
Dr. Harismendy on the Challenges Faced With Molecular Testing in DCISOlivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.
Latest:
Dr Pal on the Preliminary Efficacy of DFF332 in Advanced ccRCCSumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.
Latest:
Future Directions in Precision Medicine: An Evolving Treatment LandscapeClosing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Latest:
Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple MyelomaEmma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.
.jpg?fit=crop&auto=format)
